Showing results (21-30 of 62) with videos related to
Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|October 18, 2021
Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patientsShelby Barnett, Farina Hellmann, Elizabeth Parke, et al.Cancer Letters|April 7, 2015
SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastomaLaura Evans, Lindi Chen, Giorgio Milazzo, et al.Cell Cycle (Georgetown, Tex.)|December 19, 2006
The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damageEmma Bell, Rakesh Premkumar, Jane Carr, et al.Cancer Research|February 11, 2010
p53 is a direct transcriptional target of MYCN in neuroblastomaLindi Chen, Nunzio Iraci, Samuele Gherardi, et al.Current Drug Targets|January 7, 2014
MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistanceGiuseppe Barone, Deborah A Tweddle, Jason M Shohet, et al.Oncotarget|November 27, 2016
Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapseLindi Chen, Angharad Humphreys, Lisa Turnbull, et al.European Journal of Cancer (Oxford, England : 1990)|August 2, 2015
Carboplatin therapeutic monitoring in preterm and full-term neonatesGareth J Veal, Julie Errington, James Hayden, et al.Cancer|January 13, 2004
Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behaviorTamás Tornóczky, Endre Kálmán, Pál G Kajtár, et al.Cancers|April 30, 2021
Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical TrialGareth J Veal, Deborah A Tweddle, Johannes Visser, et al.Cell Cycle (Georgetown, Tex.)|November 5, 2011
Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expressionJane Carr-Wilkinson, Rebecca Griffiths, Rebecca Elston, et al.Pageof 7